Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells

FANGQIONG LI¹, HUAIZHONG CUI², XIN JIN¹, XIAOTING GONG¹, WEI WANG¹* and JUAN WANG¹*

¹Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012; ²Department of Clinical Laboratory, XiXi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, P.R. China

Received October 15, 2019; Accepted January 29, 2020

DOI: 10.3892/or.2020.7542

Abstract. The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, is used widely to treat non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Unfortunately, the acquired drug resistance promoted by epithelial-mesenchymal transition (EMT) markedly limits the clinical effects and remains a major barrier to a cure. Our previous isobaric tags for relative and absolute quantitation-based proteomics analysis revealed that the E-cadherin protein level was markedly upregulated by triptolide (TP). The present study aimed to determine whether TP reverses the gefitinib resistance of human lung cancer cells by regulating EMT. It was revealed that TP combined with gefitinib synergistically inhibited the migration and invasion of lung adenocarcinoma cell line A549; the combination treatment had a significantly better outcome than that of TP and gefitinib alone. Moreover, TP effectively increased the sensitivity of drug resistant A549 cells to gefitinib by upregulating E-cadherin protein expression and downregulating the MMP9, SNAIL, and vimentin expression levels. The dysregulated E-cadherin expression of gefitinib-sensitive cells induced gefitinib resistance, which could be overcome by TP. Finally, TP combined with gefitinib significantly inhibited the growth of xenograft tumors induced using gefitinib-resistant A549 cells, which was associated with EMT reversal and E-cadherin signaling activation in vivo. The present results indicated that the combination of TP and TKIs may be a promising therapeutic strategy to treat patients with NSCLCs harboring EGFR mutations.

Introduction

Lung cancer is the one of the leading causes of cancer mortality in the world, and non-small-cell lung cancer (NSCLC) accounts for nearly 85% of all lung cancers (1). Gefitinib, a typical reversible EGF receptor tyrosine kinase inhibitor (EGFR-TKI), has a marked therapeutic effect in NSCLC patients with EGFR mutations, and has been used widely as the first-choice treatment for NSCLC (2,3). However, despite the excellent initial clinical responses, almost all responding patients eventually develop different degrees of resistance within one year (2-4). Hence, reversal of the resistance to EGFR-TKIs is an urgent requirement for lung cancer therapy.

In recent years, certain Chinese herbal medicines have exhibited notable effects on drug resistance (5). Previous studies have found that curcumin (6), scorpion venom (7) and bufalin (8) could delay the emergence of EGFR-TKI resistance or inhibit drug resistance via different signaling pathways. Clinical trials have begun to utilize Chinese herbal medicines combined with EGFR-TKIs to treat lung cancer.

Among the Chinese herbal medicines, triptolide (TP), a purified diterpenoid from Tripterygium wilfordii Hook.f. (TWHF), exhibits promising potential in reversing drug resistance (9). Previous studies confirmed that TP has many biological properties, including immunosuppressive and anti-inflammatory effects (10). An increasing number of preclinical studies have demonstrated that TP has strong anti-tumor activities. As an adjuvant therapeutic agent, TP has been revealed to enhance the effect of some anticancer agents at low doses, such as hydroxyamptothecin (11) and fluorouracil (12), and increase the sensitivity of drug resistant cells to chemotherapeutics (9,13,14), rendering the combination superior to mono-therapy. However, the molecular mechanisms by which TP induces inhibition of drug resistance and sensitization are unclear. Previously, we used high-sensitivity isobaric tags for a relative and absolute quantitation technique and observed that TP treatment caused abnormal expression of proteins involved in a variety of biological processes. In particular, the increase in E-cadherin was particularly pronounced (15). E-cadherin is a core protein of epithelial-mesenchymal transition (EMT) and is involved in cancer invasion and metastasis (16). E-cadherin is closely related to molecular treatment targeting EGFR resistance and sensitivity. Increased expression of E-cadherin enhanced the sensitivity of tumor cells to the EGFR inhibitor.

Contributed equally

Key words: triptolide, gefitinib, NSCLC, E-cadherin, EMT

Correspondence to: Dr Juan Wang or Professor Wei Wang, Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, 234 Gucui Road, Hangzhou, Zhejiang 310012, P.R. China E-mail: wangjuanzju@163.com E-mail: wangweihz8@163.com

*Contributed equally
gefitinib, while knockdown of E-cadherin in parental cells induced gefitinib resistance and stemness (17-19). Thus, it was speculated that E-cadherin may participate in the development of sensitivity or resistance to EGFR-TKIs, and play a role in the complex intercellular regulation.

In the present study, it was revealed that TP combined with gefitinib had a synergistic inhibitory effect on the proliferation, migration, and invasion of A549 cells, which are resistant to gefitinib. The effect of TP against gefitinib resistance was attributed to its ability to reverse EMT by upregulating E-cadherin levels and inhibiting cell proliferation. In addition, this combinational therapy reduced the tumor volume more effectively than gefitinib or TP alone in a xenograft mouse model, and this synergistic interaction was associated with the ability of TP to reverse EMT. Thus, evidence is provided that the combination of TP and gefitinib could overcome TKI resistance in patients with NSCLC with EGFR mutations and could lead to the development of new combinatorial therapies for lung cancer.

Materials and methods

Chemicals. TP was purchased from Sigma-Aldrich; Merck KGaA. The molecular formula of TP is C_{20}H_{24}O_6, it has a molecular weight of 360.4 Da, and a purity≥98%. Gefitinib was also purchased from Sigma-Aldrich; Merck KGaA. The molecular formula of gefitinib is C_{22}H_{26}ClFNO_4, it has a molecular weight of 446.90 Da and purity≥98%. Both TP and gefitinib were stored in dimethyl sulfoxide (DMSO) at −20°C. penicillin and 100 µg/ml streptomycin), and HEPES (25 mM L-glutamine (2 mM), 1% penicillin-streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin), and HEPES (25 mM) according to the supplier’s instruction manual. Cells were incubated in a humid incubator containing 5% CO_2 at 37°C.

The gefitinib-resistant human lung adenocarcinoma cell line (A549/G) was established by increasing the gefitinib concentration. Briefly, A549 cells with 80% fusion were first treated with 5 µg/ml gefitinib for 24 h. The surviving cells were cultured for further cycles with increased doses of gefitinib (10 µg/ml and 15 µg/ml), until the A549 cells grew steadily in the medium with 15 µg/ml gefitinib. The resistance index of A549/G was detected using a Cell Counting Kit-8 assay (Beyotime Institute of Biotechnology), and calculated according to the equation of the half maximal inhibitory concentration: IC_{50} (A549/G)/IC_{50} (A549), which provided a resistance index of 5.48.

Another gefitinib-resistant human lung adenocarcinoma cell line (A549/siE-cad) was established using lentivirus-mediated small hairpin RNA (shRNA) to attenuate E-cadherin (CDH1) expression in the A549 cell line. The siRNA targeting CDH1 was cloned into the pLV-shRNA-EGFP (2A) Puro vector. The shRNA sequence for CDH1 was as follows: GGATCC-GCC CACAGATCCATTCTTGTGAGCAAGAATGGATC TGGGTTTTT-GATTC. The generated vectors were confirmed by DNA sequencing.

Transfection. The 293T cells were cultured in 10-cm dishes at a density of 4.0x10^5. Then, 500 µl of opti-MEM containing 5 µg of lentiviral interference vector targeting E-cadherin, 3.75 µg of pH vector, and 1.25 µg of pH2 vector was added into 500 µl of opti-MEM including 20 µl of Lipofectamine 2000, the mixture was incubated at room temperature for 20 min and added dropwise to the 293T cells. The medium was replaced with serum-free DMEM at 5 h post-transfection. The lentiviral particles were harvested by ultracentrifugation at 82,700 x g for 48 h after transfection. Cells were infected with the harvested lentiviruses (siE-cad) at a multiplicity of infection (MOI) of 20. The optimal infection condition was confirmed by observing the cells expressing the green fluorescent protein at 72 h after infection. Puromycin (2 µg/ml) was used to screen for stably infected cells. The resistance index of cells with stably interfered CDH1 (A549/siE-cad) was detected by Cell Counting Kit-8, and calculated, according to the equation: IC_{50} (A549/siE-cad)/IC_{50} (A549), providing a resistance index of 2.95.

Mouse model. Male BALB/c mice (4 weeks old) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. [SCXX (HU) 2017-0005]. The body weight ranged from 18 to 22 g. All mice were fed with standard mouse food and tap water and maintained under conditions of 25°C with a 12-hour light/dark cycle. The A549/siE-cad cells (2x10^6) were injected subcutaneously into the underarms of the right forelimbs of 6-week-old BCLB/c mice. After 3 weeks, all mice were randomly divided into four groups of five. These mice were administered with drugs or saline (mock) via abdominal administration every day for 4 weeks as follows: The control group was administered with NaCl [0.01 ml/g body weight (BW)], the TP-treated group was administered with TP (0.5 mg/kg BW), the gefitinib-treated group (G) with gefitinib (50 mg/kg BW), the TP+G group with TP (0.5 mg/kg BW) and gefitinib (50 mg/kg BW). The body weight and tumor size were recorded every two days; the tumor volume was calculated as: A x b x h/2 (mm^3) (a indicated the long diameter, and b the short diameter). Subsequently euthanasia was performed in accordance with the Guidelines for Euthanasia of Rodents Using Carbon Dioxide issued by the National Institutes of Health. At the end of 4 weeks, all animals were euthanized by carbon dioxide in their home cage placed in special transparent chambers. The chambers were connected with compressed carbon dioxide in a gas cylinder and flow controller. The gas replacement rate was 28% of container volume/min. Death was further verified by cardiac arrest and cadaveric rigidity. Their tumors were collected, paraffin-embedded, and then serially sectioned for subsequent hematoxylin staining and immunohistochemistry (IHC).

Cell Counting Kit-8 assays (CCK-8). The viability of cells treated with different drugs was detected using CCK-8 assay (Beyotime Institute of Biotechnology). The A549 cells were exposed to various concentrations of TP (0, 1, 2, 4, 8, 16 and 32 ng/ml) and gefitinib (0, 0.627, 1.25, 2.5, 5, 10 and 20 µg/ml),
alone or in combination, for 24, 36 and 48 h, respectively, as indicated. Cell viability was evaluated according to manufacturer’s instructions. The combination index (CI), resistance index (RI), and IC_{50} values were calculated based on the data from the cell viability assays. The optimal combined concentration of TP and gefitinib was determined by CI<1, which indicated that the effect of two drugs was synergistic. The RI equation was as follows: IC_{50} (A549/G)/IC_{50} (A549), or IC_{50} (A549/siE-cad)/IC_{50} (A549).

Cell migration and invasion. Cell migration and invasion were determined using a Transwell system (product no. 3422; Corning, Inc.) with 8.0-µm diameter pores. For the invasion assays, 45 µl diluted Matrigel was pre-coated on the Transwell membranes. A total of 5x10^4 cells were seeded into the upper chamber, and 20% FBS-containing medium was seeded into the lower chamber to induce cell migration and invasion. After 12 or 48 h of incubation (12 h for the migration assays and 48 h for the invasion assays), the cells on the upper surface of the filter were removed, and then the residual cells in the Transwell chambers were fixed with 4% paraformaldehyde at 4°C for 10 min, stained with crystal violet (0.1%, w/v) at room temperature for 5 min, and photographed under a microscope (Olympus Corp.). Five fields were selected at random, and the number of cells was counted in each field. Experiments were performed three times independently.

Western blot analysis. The prepared cells were harvested to extract proteins by enhanced RIPA lysis buffer (P0013B; Beyotime Institute of Biotechnology), and its components included 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA, leupeptin and protease inhibitors. The concentration was determined using a BCA protein assay kit (735094; Roche Diagnostics). The proteins (20 µg) were separated using 8% SDS-PAGE and then transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Inc.). Finally, the samples were observed and quantified under a light microscope.

Immunohistochemistry. The collected tumor slides were dewaxed and rehydrated. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 5 min. The collected tumor slides were then washed with phosphate-buffered saline (PBS) at room temperature and incubated in the TUNEL Reaction Mixture at 37°C. Thereafter, incubation with converter-POD solution was carried out at 37°C. The slides were incubated with diaminobenzidine (DAB) and stained with hematoxylin. Samples were dehydrated using graded ethanol, vitiﬁed by dimethylbenzene and deposited in neutral resins. Finally, the samples were observed under a light microscope.

Statistical analysis. The results are expressed as the means ± SD. One or two-way ANOVA followed by Tukey’s, Dunnett’s and Sidak’s multiple comparisons test in GraphPad Prism 6 (GraphPad Software) were used to analyze the statistical significance between two groups. A P-value<0.05 was considered to indicate a statistically significant difference.

Results

Combined treatment with TP and G induces enhanced inhibition of A549 cell viability. First, the effect of TP or G alone was assessed on the A549 cells. As revealed in Fig. 1A, both TP and G induced a marked dose-dependent inhibition of A549 cell viability, and the combined treatment with TP and G induced a significantly increased inhibition of A549 cell viability compared to TP or G alone. The inhibitory effect of TP and G alone gradually increased with prolonged exposure time (Fig. 1B and C). The 50% growth inhibition (IC_{50}) at 48 h for TP and G was 10.985 ng/ml and 5.801 µg/ml respectively. Next, the combined effect of TP and G were evaluated, and the data revealed similar dose- and time-dependent inhibitory
Table I. CI and IC<sub>50</sub> analysis for TP and G combination treatment in A549 cells.

| Exposure time (h) | TP (ng/ml) | G (µg/ml) | TP (ng/ml) | G (µg/ml) | CI |
|------------------|------------|-----------|------------|-----------|----|
| 24               | 21.35      | 10.10     | 9.27       | 5.80      | 1.01 |
| 36               | 16.05      | 8.87      | 7.99       | 4.99      | 1.06 |
| 48               | 10.99      | 5.80      | 4.23       | 2.64      | 0.84 |

CI, combination index; TP, triptolide; G, gefitinib.

Figure 1. Effect of TP and G, alone or in combination, on A549 cell viability. (A) A549 cells were treated with the indicated concentrations of TP (1, 2, 4, 8, 16, and 32 ng/ml) and G (0.627, 1.25, 2.5, 5, 10, and 20 µg/ml) alone or in combination for 24 h. Green '*' indicates statistical differences between 'TP+G' and 'G', and the red '#' represents statistical differences between 'TP+G' and TP. (B) The individual effects of TP on A549 cell growth at 24, 36, and 48 h. A549 cells were treated with graded concentrations of TP (1, 2, 4, 8, 16, and 32 ng/ml, respectively). Statistical differences between mock and treated groups at 24, 36 and 48 h were respectively indicated with black '*', red '+' and green '&'. (C) The individual effects of G on A549 cell growth at 24, 36, and 48 h. A549 cells were treated with graded concentrations of G (0.627, 1.25, 2.5, 5, 10, and 20 µg/ml, respectively). Statistical differences between mock and treated groups at 24, 36 and 48 h were respectively indicated with black '*', red '+' and green '&'. (D) The combined effects of TP and G on A549 cell growth at 24, 36, and 48 h. A549 cells were treated with the combined concentrations of TP (1, 2, 4, 8, 16, and 32 ng/ml, respectively) and G (0.627, 1.25, 2.5, 5, 10, and 20 µg/ml, respectively). Statistical differences between mock and treated groups at 24, 36 and 48 h were respectively indicated with black '*', red '+' and green '&'. Two-way ANOVA followed by Tukey’s and Dunnett’s multiple comparisons test were used to analyze differences between groups. TP, triptolide; G, gefitinib.

effects on the A549 cells, with an IC<sub>50</sub> for TP 4.228 ng/ml, and an IC<sub>50</sub> for G of 2.644 µg/ml at 48 h (Fig. 1D). These results indicated that TP had a similar inhibitory effect to G on the proliferation of A549 cells, and the combined treatment comprising TP and G more effectively inhibited A549 cell growth than TP or G alone.
Figure 2. TP and G synergistically suppress the migration of A549 cells. (A) A549 cells were treated with TP (2 ng/ml) and G (1.25 µg/ml) alone or in combination for 12 h and then stained with crystal violet. The images were representative of three independent experiments (A). The absolute number of migrated cells is presented as the means ± SD (B). Comparisons between mock and treated groups were performed by one-way ANOVA followed by Dunnett's multiple comparisons test. Statistical differences between the control and treated groups were represented by black ‘*’. TP, triptolide; G, gefitinib.

Figure 3. TP suppresses the migration and invasion of A549 cells. Transwell (A) migration and (B) invasion assays of A549 cells treated with TP (2 ng/ml). The absolute number of migrated or invaded cell is presented as the means ± SD from three independent experiments. Two-way ANOVA followed by Sidak's and Dunnett's multiple comparisons test were used to analyze differences between two groups. TP, triptolide; G, gefitinib; CDH1, E-cadherin.
Then, the combination index (CI) was calculated to estimate the synergistic effect of TP and G on A549 cells, according to the method reported by Chou and Talalay (20), in which the synergism is defined by CI<1. The CI values were 1.01 and 1.06 when A549 cells were treated with TP and G for 24 and 36 h, respectively, while it was 0.84 when the A549 cells were exposed for 48 h (Table I). This demonstrated an evident synergistic effect of TP and G on A549 cells. Based on this evidence, the effect of TP and G on cell behavior was next assessed. During the subsequent experiments, the combination of TP (2 ng/ml) and G (1.25 µg/ml) were used to treat the A549 cells, which exhibited the synergistic effect of inhibiting the growth of A549 lung adenocarcinoma cells.

TP and G synergistically suppress cell migration of A549 cells. Resistance to gefitinib results in cell metastasis; therefore, the individual or synergistic effect of TP and G on the migration of A549 cells was investigated using Transwell invasion assays. The results in Fig. 2 revealed that treatment with TP and G alone, or in combination, significantly decreased the number of migrated cells (P<0.01). The number of migrated cells in the TP+G group decreased by nearly 60% (P<0.01), which was significantly lower than that in the TP- or G-treated cells alone. These data indicated that TP played a suppressive role with G on the migration of A549 cells, and that TP combined with G induced a robust decrease in cell migration.

**TP suppresses the migration and invasion of gefitinib-resistant A549 cells.** To demonstrate the role of TP in gefitinib resistance, a gefitinib-resistant A549 cell line (A549/G) was first established. Deficiency of E-cadherin is implicated in EMT, invasion, and metastasis; therefore, an A549 cell line exhibiting stable interference of E-cadherin expression was also established (A549/siE-cad). Next, the A549/G, A549/siE-cad and control cells were plated in Transwell devices and treated with 2 ng/ml of TP. The results revealed that E-cadherin interference and gefitinib resistance both led to increased cell migration across the Transwell filters; however, TP markedly suppressed the migration of A549, A549/siE-cad, and A549/G cells (Fig. 3A). The cell invasion assay results revealed that the number of invading A549/siE-cad and A549/G cells was markedly higher than that of the control cells. TP treatment significantly impaired cell invasion of the control, A549/siE-cad, and A549/G cells (Fig. 3B). These results
indicated that TP could inhibit cell migration and invasion, and reverse the gefitinib resistance phenotype of A549/siE-cad cells and A549/G cells.

TP reverses the gefitinib resistance of A549 cells by regulating E-cadherin and MMP9. To determine the underlying molecular mechanism, proteins implicated in EMT were detected using western blotting. The levels of E-cadherin were significantly increased in the drug-treated cells. The E-cadherin expression in the TP+G-treated cells was nearly twice that in the control cells (Fig. 4A). In addition, the matrix metalloproteinase-9 (MMP9), Snail family transcriptional repressor 1 (SNAIL) and vimentin protein levels significantly decreased in the TP- and TP+G-treated cells compared with those in the control, and the G treatment induced a modest reduction of MMP9, SNAIL and vimentin protein expression, and treatment with TP+G had a synergistic effect on the levels of E-cadherin.

To determine the role of E-cadherin in TP-treated cells, the E-cadherin levels in A549, A549/siE-cad, and A549/G cells were detected. The results revealed that the E-cadherin level decreased significantly in the A549/siE-cad cells compared with that in the A549 cells and A549/G cells. TP treatment increased the E-cadherin in all three groups, especially in A549 cells (Fig. 4B). The protein expression of MMP9 and...
SNAIL in A549, A549/siE-cad and A549/G cells significantly decreased after TP treatment compared with those in their respective controls. Concurrent, TP treatment significantly increased caspase-3 in A549, A549/siE-cad and A549/G cells. These results indicated that TP suppressed cell migration and invasion of A549, A549/siE-cad, and A549/G cells by regulating the E-cadherin and MMP9 signaling pathway, and induced apoptosis of these cells by increasing the levels of caspase-3.

**Combination of TP and G synergistically inhibits A549/siE-cad cell xenografts by inducing apoptosis.** To further verify the effect of TP on A549 cell tumor induction, an A549/siE-cad tumor-bearing mouse model was produced, and TP, G, and TP/G were administrated to these mice. The results revealed that there were no significant differences in body weight (BW) among the TP, G and TP+G-treated groups. The BW of the three treated groups was slightly heavier than that of the control group, while there was no statistical difference between the treated and control groups (Fig. 5A). With regards to the tumor volume, TP, G and TP/G treatment significantly reduced the tumor volume in a time-dependent manner (Fig. 5B). The tumor volume of the TP+G group was significantly smaller than that of TP, G and control groups. These results indicated that both TP and G have inhibitory effects on tumorigenesis of A549/siE-cad tumor-bearing mice in vivo, and that the inhibitory effect of TP+G treatment was greater than that of either T or G alone.

Next, H&E analysis was performed to investigate the pathological changes in the tumors of each group. Treatment with T or G alone induced nuclear aberration, cell degradation, and necrosis, and treatment with T+G enhanced these effects (Fig. 5C). TUNEL staining revealed that treatment with T or G alone induced significant tumor cell apoptosis, and this apoptosis was enhanced by treatment with the TP+G combination (Fig. 5D).

**Combination of TP and G induces an apoptotic pathway in gefitinib-resistant A549 cells that induces tumors by regulating MMP9 and caspase-3.** IHC assays were conducted to investigate the signaling pathways involved in TP-induced inhibition of gefitinib resistance in A549 cells during tumor induction. As revealed in Fig. 5E, the protein level of E-cadherin was significantly increased after treatment with TP+G, it was also increased in the TP- and G-treated tumor groups, while the statistical difference between the control and monotherapy, or monotherapy and combination therapy was not significant. The protein level of MMP9 was significantly decreased after...
TP, G and TP+G treatment, and the inhibition in TP+G was greater than that in TP or G alone. In addition, caspase-3 protein expression increased in the TP-, G- and TP+G-treated tumors, and the increase in the TP+G group was higher than that in the TP or G treatment groups. These results indicated that both TP and G could upregulate E-cadherin and caspase-3 expression levels, and downregulate MMP9 protein levels in A549/siE-cad tumor-bearing mice in vivo, however, treatment with TP+G exhibited a more potent effect.

**Discussion**

Currently, molecular targeted therapy is the preferred treatment for NSCLC. Gefitinib is a typical representative of molecular targeted drugs for lung cancer and belongs to the EGFR-TKI class of drugs (21). However, nearly all patients treated with gefitinib deteriorate due to the emergence of EGFR-TKI acquired resistance, for which no effective therapy is currently available (22,23). Emerging studies have reported that certain Chinese medicines could reduce gefitinib-induced drug resistance, including TP (24,25). However, the role and mechanism of TP in gefitinib-induced drug resistance in NSCLC is unclear. In the present study, it was confirmed that TP inhibited the migration and invasion of A549 cells to a greater extent than G, and this effect was further enhanced using the combination of G and TP, indicating that TP and gefitinib have a synergistic effect on A549 cells. Subsequently, a gefitinib-resistant A549 cell line (A549/G) was established to investigate whether TP regulated drug resistance. The migration and invasion abilities of gefitinib-resistant cells were enhanced compared with their parental gefitinib-sensitive A549 cells. TP treatment effectively inhibited the migration and invasion of the gefitinib-resistant cells, indicating that TP suppressed gefitinib resistance. These results verified that TP acts as an adjuvant therapeutic agent at low doses to enhance anticancer effectiveness (9,26,27).

Increasing numbers of in vitro and in vivo studies have reported various possible molecular mechanisms of drug resistance to gefitinib, among which EGFR gene amplification and EMT are the most studied (28-30). Rho et al reported that EMT resulting from repeated exposure to gefitinib blunted the sensitivity of A549 cells to EGFR inhibitors (31). Induction of EMT contributed to the decreased efficacy of therapy in primary and acquired resistance to gefitinib (32). E-cadherin is involved in the formation of cell-to-cell adhesions junctions that assemble adjacent epithelial cells and maintains their quiescence. Downregulation of E-cadherin is considered the core element of EMT (33,34). Herein, it was revealed that TP significantly increased the levels of E-cadherin both in gefitinib-sensitive and gefitinib-resistant A549 cells, indicating that TP inhibited EMT and increased E-cadherin sensitivity by increasing E-cadherin levels. SNAIL, as the core transcription factor regulating EMT, inhibits the expression of CDH1 by competitive binding to the E-box sequence in the CDH1 promoter region, and induces mesenchymal proteins such as vimentin and MMP-9, which further promote EMT (35,36). Vimentin was originally identified as a specific marker of mesenchymal tumors; however, it was later revealed to be associated with cancer cell expression and prognosis in patients, and its expression is widely considered as a necessary condition to enhance cancer invasion and metastasis (37). MMP9 is a matrix metalloproteinase secreted by tumor cells that weakens the natural barrier and promotes tumor cell metastasis by degrading the tumor extracellular matrix (ECM). Therefore, a decrease of MMP9 expression plays an important role in inhibiting EMT (38,39). Given the role of SNAIL in the regulation of EMT markers, it was speculated that the decrease in SNAIL levels induced by TP led to a reduction in MMP9 and vimentin, and increased the levels of E-cadherin. The combined effect of these changes resulted in EMT inhibition.

Given the beneficial effects of TP in inhibiting EMT and increasing gefitinib sensitivity, gefitinib-resistant A549 cells were established by interfering with E-cadherin expression and continuous exposure to gefitinib to confirm the ability of TP to increase the sensitivity of gefitinib-resistant cells. The results revealed that the migration and invasion of gefitinib-resistant cells was significantly enhanced. Immunoblotting assays confirmed the loss of E-cadherin, and gain of MMP9 and caspase-3. In addition, TP combined with gefitinib still exhibited an inhibitory effect on the tumors derived from A549/siE-cad cells by upregulating the levels of E-cadherin and caspase-3, and decreasing those of MMP9. Caspase-3 is a pivotal junction protein in apoptotic pathways, which can be activated by other activated caspas and then induces apoptosis (37,38). The present results were consistent with previous studies which revealed that E-cadherin expression potentiates sensitivity to the apoptotic effects of gefitinib (31,32). The increase of E-cadherin is accompanied by the occurrence of apoptosis, which synergistically inhibits tumor growth (40). In a previous study MMP9 inhibition by tetramethylpyrazine was related to vascular endothelial cell apoptosis (41). As for vimentin, it was involved in the emergence of apoptosis induced by peptidylarginine deiminase 2 and TNF-α (42,43). Furthermore, the interference with SNAIL signaling by TPD52L2 induced apoptosis of glioblastoma cells (44). In fact, the inhibition of MMP9, SNAIL, and vimentin proteins always coexists with apoptosis (45). In conclusion, these results indicated that TP could reverse gefitinib resistance of A549 cells by suppressing the EMT signaling pathway and inducing apoptosis.

Acquired resistance to EGFR-TKIs is almost inevitable in patients with NSCLC with EGFR mutations. Management of TKI resistance has become the focus of research to increase the overall survival of these patients. In the present study, it was demonstrated, for the first time to the best of our knowledge, that TP treatment overcomes TKI resistance in vitro and in vivo by reverting EMT. Further studies are required to develop the synergistic anticancer action and drug resistance reversal effect of TP combined with gefitinib for clinical use.

**Acknowledgements**

Not applicable.

**Funding**

The present study was funded by the Natural Science Foundation of Zhejiang Province (grant. no. LQ17H290001) and the Natural Science Foundation of China (grant. no. 81774026).
Availability of data and materials

The analyzed datasets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions

FL, JW and WW conceived and designed the experiments. FL, JW and XG performed the experiments. HC and XJ collected, analyzed and interpret the data. FL drafted the manuscript. JW and FL revised the manuscript, WW and XG provided important intellectual content. All authors read and approved the final manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All animal treatment protocols were approved by the Institutional Animal Care and Use Committee of The Tongde Hospital of Zhejiang Province.

Patient consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interests.

References

1. Malhotra J, Jabbour SK and Aisner J: Current state of immuno-therapy for non-small cell lung cancer. Transl Lung Cancer Res 6: 196-211, 2017.
2. Liao BC, Lin CC, Lee JH and Yang JC: Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer 110: 7-13, 2017.
3. Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q, Wang W, Xu K, Yao J and Guo R: LINCO00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC. Mol Ther Nucleic Acids 16: 155-161, 2019.
4. Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z and Xu Y: Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 20: 2714-2726, 2014.
5. Zhang Y, Wu Z, Yu H, Wang H, Liu G, Wang S and Ji X: Chinese herbal medicine wuxia changfu formula reverses cell adhesion-mediated drug resistance via the integrin b1-PI3K-AKT pathway in lung cancer. J Cancer 10: 293-304, 2019.
6. Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG and Li J: Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J Exp Clin Cancer Res 38: 254, 2019.
7. Almalahty A, Farajallah A, Abualhajaja A and Al-Balas Q: A3, a Scorpion venom derived peptide analogue with potent antimicrobial and potential antibiofilm activity against clinical isolates of multi-drug resistant gram positive bacteria. Molecules 23: E1603, 2018.
8. Cao F, Gong YB, Kang XH, Lu ZH, Wang Y, Zhao KL, Miao ZH, Liao MJ and Xu ZY: Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicol Appl Pharmacol 379: 114662, 2019.
9. Hou ZY, Tong XP, Peng YB, Zhang BK and Yan M: Broad targeting of triptolide to resistance and sensitization for cancer therapy. Biomed Pharmacother 104: 771-780, 2018.
10. Qiu D and Kao PN: Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4: 1-18, 2003.
11. Meng G, Wang W, Chai K, Yang S, Li F and Jiang K: Combination treatment with triptolide and hydroxyamphetamine synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs andAkt signaling pathways. Int J Oncol 46: 1007-1017, 2015.
12. Xu B, Guo X, Mathew S, Armesilla AL, Cassidy J, Darling JL and Wang W: Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett 291: 200-208, 2010.
13. Xie CQ, Zhou F, Zuo J, Li X, Chen Y and Chen JW: Triptolide exerts pro-apoptotic and cell cycle arrest activity on persistent human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways. Oncol Lett 12: 3586-3590, 2016.
14. Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee SE and Yeon JS: Synergistic antimutator effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J Urol 193: 1016-1022, 2015.
15. Li F, Zhao D, Yang S, Wang J, Liu Q, Jin X and Wang W: ITRAQ-Based proteomics analysis of triptolide on human A549 lung adenocarcinoma cells. Cell Physiol Biochem 45: 917-934, 2018.
16. Koundis A, Lu R, Pence LJ and Anastasiadis PZ: A central role of E-cadherin signaling in cancer. Exp Cell Res 358: 78-85, 2017.
17. Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al: Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene 38: 455-468, 2019.
18. Rastogi I, Rajanna S, Webb A, Chhabra G, Foster B, Webb B and Puri N: Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun 477: 937-944, 2016.
19. Idzerdzig T, Kellen J, Osade C, Singh S, Woodman JA, Garcia C and Puri N: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun 496: 770-777, 2018.
20. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
21. Yin J, Hu W, Pan L, Fu W, Dai L, Jiang Z, Zhang F and Zhao J: Let-7 and miR17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer. Oncol Rep 42: 495-508, 2019.
22. Fiore M, Trecca P, Perrone G, Amato M, Riggi D, Troiano L, D’Angelillo RM and Ramella S: Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. Tumori 105: NP12-NP16, 2019.
23. Pao W, Miller VA, Politi KA, Riely GI, Somwar R, Zakowski MF, Kris MG and Varmaus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
24. Zhang J, Sun L, Cui J, Wang J, Liu X, Aung TN, Qu Z, Chen Z, Adelson DL and Lin L: Yiguchan tang reduces gefitinib-induced drug resistance in non-small-cell lung cancer by targeting apotosis and autophagy. Cytometry A 97: 70-77, 2019.
25. Meng J, Chang C, Chen Y, Bi F, Ji C and Liu W: EGCC overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC. Oncotarget 12: 6033-6043, 2019.
26. Wang R, Ma X, Su S and Liu Y: Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751. Future Med Chem 10: 1947-1955, 2018.
27. Han Y, Huang W, Liu J, Liu D, Cui Y, Huang R, Yan J and Lei M: Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells. Theranostics 7: 1914-1927, 2017.
28. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET amplification occurs at second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
29. Schueler J, Tschuch C, Klinger K, Bug D, Peille AL, de Koning L, Goschke A, Widemann B, Stremmel W and Thurner M: Acquired resistance towards EGFR inhibitor gefitinib in a patient-derived xenograft model of non-small cell lung cancer and subsequent molecular characterization. Cells 8: E740, 2019.
30. Suda K, Mizuuchi H, Maehara Y and Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31: 807-814, 2012.

31. Rho JK, Choi YJ, Lee JK, Ryu BY, Na II, Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.

32. Jakobsen KR, Demuth C, Sorensen BS and Nielsen AL: The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res 5: 172-182, 2016.

33. Asakura T, Yamaguchi N, Ohkawa K and Yoshida K: Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1. Int J Oncol 46: 2251-2260, 2015.

34. Gloushankova NA, Zhitnyak IY and Rubtsova SN: Role of epithelial-mesenchymal transition in tumor progression. Biochemistry (Mosc) 83: 1469-1476, 2018.

35. Papiewska-Pajak I, Kowalska MA and Boncza J: Expression and activity of SNAIL transcription factor during epithelial to mesenchymal transition (EMT) in cancer progression. Postepy Hig Med Dosw (Online) 70: 968-980, 2016.

36. Shimokawa M, Haraguchi M, Kobayashi W, Higashi Y, Matsushita S, Kawai K, Kanekura T and Ozawa M: The transcription factor Snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2. Biochem Biophys Res Commun 430: 1078-1082, 2013.

37. Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG IV, Martin WD, Grossniklaus HE, Sica G, Gilberti-Ross M and Marcus AL: Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin Cancer Res 24: 420-432, 2018.

38. Huang M and Xin W: Matrine inhibiting pancreatic cells epithelial-mesenchymal transition and invasion through ROS/NF-xB/MMPs pathway. Life Sci 192: 55-61, 2018.

39. Sun Q, Yang Z, Li P, Wang X, Sun L, Wang S, Liu M and Tang H: A novel miRNA identified in GRSF1 complex drives the metastasis via the PIK3R3/AKT/NF-xB and TIMP3/MMP9 pathways in cervical cancer cells. Cell Death Dis 10: 636, 2019.

40. Han B, Zhang YY, Xu K, Bai Y, Wan LH, Miao SK, Zhang KX, Zhang HW, Liu Y and Zhou LM: NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer. Am J Cancer Res 8: 810-823, 2018.

41. Hu IZ, Wang XK, Cao Y, Li DZ, Wu TD, Zhang T, Xu DQ and Lu HB: Tetramethylpyrazine facilitates functional recovery after spinal cord injury by inhibiting MMP2, MMP9, and vascular endothelial cell apoptosis. Curr Neurovasc Res 14: 110-116, 2017.

42. Hsu PC, Liao YF, Lin CL, Lin WH, Liu GY and Hung HC: Vimentin is involved in peptidylarginine deiminase 2-induced apoptosis of activated Jurkat cells. Mol Cells 37: 426-34, 2014.

43. Yang L, Tang L, Dai F, Meng G, Yin R, Xu X and Yao W: Raf-1/CK2 and RhoA/ROCK signaling promote TNF-α-mediated endothelial apoptosis via regulating vimentin cytoskeleton. Toxicology 389: 74-84, 2017.

44. Qiang Z, Jun-Jie L, Bai W, Hong L, Hong L, Bing-Xi L, Lei C, Wei X, Ya-Wei L, Huang A, Song-Tao Q and Yun-Tao L: TPD52L2 impacts proliferation, invasiveness and apoptosis of glioblastoma cells via modulation of wnt/β-catenin/snail signaling. Carcinogenesis 39: 214-224, 2018.

45. Bao X, Ren T, Huang Y, Ren C, Yang K, Zhang H and Guo W: Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. Int J Oncol 50: 477-486, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.